Stocks To Buy Now

Blog


Charting the Future of Biopharma and Medical Devices: DGE’s 2nd Chief Commercial Officer Summit Convenes Industry Leaders in Philadelphia

DGE invites biotech, pharmaceutical and medical device leaders to attend the 2nd Chief Commercial Officer Summit to be held at The Bellevue Hotel, Philadelphia, PA, October 4-5, 2023. The much-awaited summit aims to chart the remarkable future of the biotech, pharmaceutical and medical device industries. The landmark event will feature a gathering of thought leaders and visionaries dedicated to driving commercial growth in the industry.

The role of Chief Commercial Officers (“CCOs”) has gained more significance with the progression of the life sciences landscape. The 2nd Chief Commercial Officer Summit provides a unique platform to explore key strategies for advancing commercial development, improving product value, and enhancing patient access. The summit explicitly caters to the challenges of the biopharma and medical device sectors, offering customized solutions and insights to the attendees.

Focused on Market Expansion and Patient Access

The 2nd Chief Commercial Officer Summit is committed to fostering brilliance in the biopharma and medical device industries. It’s an incredible platform to build connections, gain insights, and shape the future of commercial excellence. The summit provides attendees with a unique opportunity to explore the options to access new markets and territories, opening new possibilities for expansion and growth. The industry leaders will share their strategies to ensure the profitability and success of the biopharma and medical device products.

Who will attend:

  • Chief Commercial Officers
  • Commercialization Experts
  • Commercial Operations Professionals
  • Product Launch Leaders
  • Market Access Specialists
  • Digital Innovators
  • Reimbursement Specialists
  • Marketing Executives
  • Value Strategists
  • Pricing Experts
  • Gross-to-Net Analysts
  • Franchise Leaders
  • Branding Specialists
  • Sales Leaders
  • Finance Professionals
  • Business Development Executives
  • Licensing Specialists
  • Venture Capitalists
  • Distribution Channel Planners
  • Portfolio Managers

Interested participants should register for the event now.

To learn more, please visit https://ibn.fm/7trPx.

From Our Blog

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

May 9, 2025

A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid manufacturers […]

Rotate your device 90° to view site.